Floatz logo

Liraglutide

Neurodevelopmental Disorder

Yale Universityprotein_peptideEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neurodevelopmental Disorder cohort.

Asset / SponsorPhaseRating
Sertraline
Holland Bloorview Kids Rehabilitation Hospital
Phase 2CCC

Same molecule, other indications

Liraglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
84 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →